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occurrence of a surgical site infection (SSI) examined by wound
closure method. Post-CABG SSIs were identiﬁed by ICD-9,
DRG, and APR-DRG codes during the initial hospital admis-
sion and re-admissions within 2 months of the initial hospital-
ization, as well as exposure to antimicrobial drugs from post-
operative day 9 to 60 during the initial hospital admission.
RESULTS: A total of 59,006 patients qualiﬁed for the study;
38,799 sutures only, 10,262 sutures/DERMABOND, 8180
sutures/staples, and 1765 sutures/staples/DERMABOND. The
groups were similar at baseline regarding patient and disease
characteristics. The lowest rate of post-CABG SSI was found in
the sutures/DERMABOND group (4.3%, 95% CI = 3.9%–
4.7%), followed by sutures only (5.3%, 95% CI = 5.1%–
5.5%), sutures/staples (6.2%, 95% CI = 5.7%–6.8%), and
sutures/staples/DERMABOND (7.1%, 95% CI = 6.0%–8.4%).
The mean (median) hospitalization cost for all patients without
post-CABG SSI was $28,061 ($25,527), compared to $47,874
($40,062) for all CABG patients who developed SSI. CON-
CLUSIONS: The results of this study suggest that the use of
both DERMABOND Topical Skin Adhesive and sutures for
wound closure following CABG surgery reduces the rate of SSI
and improves clinical outcomes. SSI following CABG surgery
imposes a signiﬁcant economic burden in terms of additional
hospitalization costs.
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OBJECTIVES: The purpose of this study was to determine the
most frequently used clopidogrel dosing regimen in the hospital
setting for acute coronary syndrome (ACS) patients undergoing
percutaneous coronary intervention (PCI). METHODS: This
was a retrospective study using the IMS Health Acute Cardio-
vascular Analyzer. This is an ongoing physician-reported registry
dating from 2005 in Germany, France, Italy, Spain and the UK.
Data collection timeframe reported here was December 2006–
November 2007. The standard dose clopidogrel group was
deﬁned as 300 mg. Demographic and health characteristics
were compiled for the entire cohort and by country. Study data
are shown as summary (or descriptive) statistics. RESULTS:
There were 4455 ACS patients who received clopidogrel and
underwent PCI. Patient count by country was: Germany
(n = 1098), France (n = 1022), Italy (n = 864), Spain (n = 804),
UK (n = 667). Mean age was 63.7  22.9 (SD) years, 46% were
age >65; 71% were male. Common co-morbidities and risk
factors were: hypertension 66.8%, dyslipidemia 74.6%, diabetes
30.6%, prior myocardial infarction (MI) 12.9%. Medications
prior to admission were: clopidogrel 15.9%, statins 34.8%,
aspirin 61.3%. The index diagnosis was: ST-elevation MI 45.0%,
non ST-elevation MI 33.1% and unstable angina 21.9%. Timing
of clopidogrel administration in relation to PCI was: 59.3%
pre-PCI, 11.8% at PCI and 17.0% after PCI (11.9% not speci-
ﬁed). Loading dose ranged from 75–900 mg. Dosage 300 mg
by country was: Germany 47.9%, France 67.8%, Italy 90.8%,
Spain 85.6%, UK 60.7%. Approximately 95% of patients were
discharged on clopidogrel but planned duration varied widely:
1–3 months (25.7%), 6–12 months (19.7%) are greater than or
equal to 12 months (26.5%). CONCLUSIONS: These 2007 data
indicate many patients received clopidogrel prior to PCI at the
300 mg dose but there was geographic variation. The vast
majority of patients received clopidogrel upon discharge, but the
planned duration of therapy varied widely. These data conti-
nue to be useful benchmarks for later comparison to treatment
guidelines.
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OBJECTIVES: To analyze the risk and costs of the ﬁrst
hypertension-associated event, compliance and persistence in
naïve hypertensive patients after initiating monotherapy with any
of the ﬁrst-line antihypertensive drug classes in Germany.
METHODS: A retrospective cohort study in the IMS Disease
Analyzer database was performed. Study subjects included all
previously untreated hypertensive adults who were free from
hypertension-associated comorbidities and were prescribed
initial monotherapy with angiotensin II receptor blockers
(ARBs), ACE-inhibitors (ACEIs), beta-blockers (BBs), calcium
channel blockers (CCBs) or diuretics. Compliance and persis-
tence were determined for each drug class separately and for the
group of non-ARBs (pooled data) within two years. The risk of
the ﬁrst hypertension-associated event (cardiovascular complica-
tions, new onset diabetes) was analyzed using a Cox regression
model adjusted for sociodemographic variables, compliance and
persistence. Based on these results average costs per event were
estimated from the German statutory health insurance perspec-
tive. RESULTS: A total of 7661 patients were identiﬁed with a
follow-up of at least 2 years. Mean follow-up was 5.6 to 6.3
years. Compliance (0.86 vs. 0.82 and 0.74, respectively) and
persistence (509 days vs. 459 and 324 days) was better with
ARBs (all p < 0.05) than with the group of non-ARBs and diuret-
ics, respectively. The risk of the ﬁrst hypertension-associated
event was higher (all p < 0.05) with diuretics (adjusted hazard
ratio (aHR) 0.68), BBs (0.79), CCBs (0.78), and the group of
non-ARBs (0.81) and was similar with ACEIs (aHR 0.93,
p = 0.37) compared to ARBs. Similar ﬁndings were found for
cardiovascular complication rates. The estimated average costs
per event for the ﬁrst event were lower with ARBs (€2339.95)
than with the other drug classes (€2531.68–€3910.47). CON-
CLUSIONS: Our real-world data indicate that initiating mono-
therapy with ARB shows signiﬁcant beneﬁts in most outcomes
including hypertension-related complications compared to other
antihypertensive drug monotherapies.
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OBJECTIVES: Economic theory suggests that health insurance
will reduce prevention activities (i.e., ex ante moral hazard). For
instance, prescription drug insurance could result in behavioral
responses that undermine the beneﬁts of increased access to
medication. In this paper, we investigate the relationship between
prescription drug insurance and preventive health behaviors
(physical activity, alcohol consumption, smoking behavior, and
weight) among elderly population. Further, we identify two sub-
groups particularly at risk of substituting prescription drugs for
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